.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
US Department of Justice
AstraZeneca
McKinsey
Harvard Business School
Argus Health
Colorcon
Fish and Richardson
Cipla
Moodys

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,435,567

« Back to Dashboard

Which drugs does patent 8,435,567 protect, and when does it expire?


Patent 8,435,567 protects SEEBRI and UTIBRON and is included in two NDAs.

This patent has one hundred and ninety-three patent family members in thirty-four countries.

Summary for Patent: 8,435,567

Title:Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
Abstract: The invention provides microparticles for use in a pharmaceutical composition for Pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.
Inventor(s): Staniforth; John Nicholas (Bath, GB), Harris; Haggis (Bristol, GB), Morton; David Alexander Vodden (Bath, GB), Bannister; Robin (Essex, GB)
Assignee: Vectura Limited (Chippenham, GB)
Application Number:13/269,025
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes8,435,567► SubscribeY
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes8,435,567► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,435,567

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0029261.5Nov 30, 2000
United Kingdom0030946.8Dec 19, 2000
United Kingdom0124010.0Oct 5, 2001

Non-Orange Book Patents for Patent: 8,435,567

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,303,991Method of making particles for use in a pharmaceutical composition► Subscribe
7,541,022Pharmaceutical formulations for dry powder inhalers► Subscribe
7,736,670Method of making particles for use in a pharmaceutical composition► Subscribe
9,351,928Method of making particles for use in a pharmaceutical composition► Subscribe
9,585,839Particles for use in a pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,435,567

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria330585► Subscribe
Austria339195► Subscribe
Austria348603► Subscribe
Austria364381► Subscribe
Austria377416► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
QuintilesIMS
Argus Health
Covington
Baxter
Queensland Health
Cipla
Daiichi Sankyo
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot